| 中文名称: | MSOP | ||||
|---|---|---|---|---|---|
| 英文名称: | MSOP | ||||
| 别名: | 2-Amino-2-methyl-3-phosphonooxypropanoic acid | ||||
| CAS No: | 66515-29-5 | 分子式: | C4H10NO6P | 分子量: | 199.1 |
| CAS No: | 66515-29-5 | ||||
| 分子式: | C4H10NO6P | ||||
| 分子量: | 199.1 | ||||
基本信息
|
产品编号： |
M60025 |
||||
|
产品名称： |
MSOP |
||||
|
CAS: |
66515-29-5 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
6个月 |
||
|
分子量： |
199.10 |
-20℃ |
1个月 |
||
|
化学名： |
|||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
5.0226mL |
25.1130mL |
50.2260mL |
|
5mM |
1.0045mL |
5.0226mL |
10.0452mL |
|
10mM |
0.5023mL |
2.5113mL |
5.0226mL |
生物活性
|
产品描述 |
第三组代谢性谷氨酸受体的选择性拮抗剂，其对 L-AP4 敏感突触前代谢性谷氨酸受体的 KD 值为 51μM。 |
|
靶点 |
KD:51μM (L-AP4-sensitive presynaptic mGluR). |
|
体外研究 |
In the presence of 200μM MSOP,a rightward parallel shift of the dose-response curve to L-AP4 is observed,with an apparent KD calculated as 51±6μM (n=3).MSOP is shown to be selective for the L-APC sensitive presynaptic mGluR,the apparent KD for the interaction of MSOP with the (1S,3S)-ACPD sensitive receptor calculated as greater than 700μM (n=3). |
|
体内研究 |
It is found that TBOA-induced antinociceptive effects are significantly blocked by intrathecal co-administration of MSOP (second phase of formalin model:F3,16=30.96,P<0.001;CFA model:F3,16=30.77,P<0.001).As expected,intrathecal TBOA (10μg) reduces the number of formalin-induced flinches and shakes by 47% of the value in the saline-treated group in the second phase (P<0.001) and blocked the CFA-induced decrease in ipsilateral paw withdrawal latency by 60% of the value in the saline-treated group (P=0.01).The number of formalin-induced flinches in the second phase in the group treated with MSOP and TBOA is increased by 56% (P=0.04) of the value in the TBOA-treated group.CFA-induced paw withdrawal latency in the group treated with MSOP and TBOA is decreased by 86% (P=0.03) of the value in the TBOA-treated group. |
推荐实验方法(仅供参考)
|
动物实验: |
|
|
Rats Male Sprague-Dawley rats (250-300g) are housed individually in cages on a standard 12h-12h light-dark cycle.Water and food are available as libitum until rats are transported to the labotatory approximately 1h before the experiments.A glutamate transporter activator,three glutamate transporter inhibitors,TBOA,DL-THA,dihydrokainate,and a selective group III mGluR antagonist MSOP are used.All drugs are dissolved in 0.9% physiological saline.To examine the role of group III mGluRs in the antinociceptive effect produced by intrathecal TBOA in the formalin model,the rats are intrathecally injected with saline (10μL;n=5),MSOP (10μg/10μL;n=5),TBOA (10μg/10μL;n=5),or MSOP plus TBOA (n=5).Ten minutes later,2% formalin (100μL) is injected into the plantar side of a hind paw and formalin-induced pain behaviors are assessed.To examine the role of group III mGluRs in the antinociceptive effect produced by intrathecal TBOA in the complete Freund’s adjuvant (CFA) model,the rats are intrathecally injected with saline (10μL;n=5),MSOP (10μg/10μL;n=5),TBOA (10μg/10μL;n=5),or MSOP plus TBOA (n=5) at 6h post-CFA and then measured paw withdrawal latencies. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
